The 'never-ending story' of the influence of blood specimen collection methods affecting the concentration, the zymographic profile and the usefulness of matrix metalloproteinases and their tissue inhibitors in multiple sclerosis diagnosis/prognosis: A landmark for limiting the misuse of serum samples [2]

Multiple Sclerosis

Volumn 13, Issue 5, 2007, Pages 687-690

  Mannello, F ^a   Tonti, G A M ^a   Canestrari, F ^a  

^a UNIVERSITY OF URBINO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

AUTOIMMUNE DISEASE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD SAMPLING; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LETTER; MULTIPLE SCLEROSIS; PATHOGENESIS; PROGNOSIS; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REFERENCE VALUE; RELIABILITY; VEIN PUNCTURE; ZYMOGRAPHY;

BLOOD SPECIMEN COLLECTION; CHEMISTRY, CLINICAL; HUMANS; MATRIX METALLOPROTEINASES; MULTIPLE SCLEROSIS; PROGNOSIS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 34250643152     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506072492     Document Type: Letter

References (41)

1. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathogenesis of the nervous system. Nat Rev Neurosci 1992; 41: 29-34.
2. Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L et al. Measurement of matrix metalloproteinases and tissue inhibitors of metaloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci 1999; 878: 212-27.
3. Opdenakker G, Nelissen I, Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol 2003; 2: 502-11.
4. Mannello F, Tonti G, Papa S. Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr Cancer Drug Targets 2005; 5: 285-98.
5. Prince HE. Biomarkers for diagnosing and monitoring autoimmune diseases. Biomarkers 2005; 10: 44-49.
6. Fainardi E, Castellazzi M, Bellini T, Manfrinato MC, Baldi E, Casetta I et al. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult Scler 2006; 12: 294-301.
7. Lichtinghagen R, Seifert T, Kracke A, Marckmann S, Wurster U, Hiedenreich F. Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 1999; 99: 19-26.
8. Mirowska D. Wicha W, Czlonkowski A, Czlonkowska A, Weber F. Increase of matrix metalloproteinase-9 in peripheral blood of multiple sclerosis patients treated with high doses of methylprednisolone. J Neuroimmunol 2004; 146: 171-75.
9. Miller KM, Ford JC, Ward GA, Palace J. Increase in 92kDa gelatinase in serum is associated with clinical relapse in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1996; 61: 225-26.
10. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999; 122: 191-97.
11. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 1999; 53: 1397-401.
12. Yushchenko M, Weber F, Mader M, Scholl U, Maliszewska M, Tumani H et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count. J Neuroimmunol 2000; 110: 244-51.
13. Liuzzi GM, Trojano M, Fanelli M, Avolio C, Fasano A, Livrea P et al. Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis. Mult Scler 2002; 8: 222-28.
14. Avolio C, Ruggieri M, Giuliani F, Liuzzi GM, Leante R, Riccio P et al. Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. J Neuroimmunol 2003; 136: 46-53.
15. Sastre-Garriga J, Comabella M, Brieva L, Rovira A, Tintore M, Montalban X. Decreased MMP-9 production in primary progressive multiple sclerosis patients. Mult Scler 2004; 10: 376-80.
16. Avolio C, Filippi M, Tortorella C, Rocca MA, Ruggieri M, Agosta F et al. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult Scler 2005; 11: 441-46.
17. Kanesaka T, Mori M, Hattori T, Oki T, Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 185-88.
18. Jung K, Laube C, Lein M, Lichtinghagen R, Tschesche H, Schnorr D et al. Kind of samples as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin Chem 1998; 44: 1060-62.
19. Jung K, Lein M, Laube C, Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001; 314: 241-44.
20. Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin Chem 2003; 49: 339-40 (Letter).
21. Makowski GS, Ramsby ML. Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal Biochem 2003; 322: 283-86.
22. Mannello F, Luchetti F, Canonico B, Papa S. Effects of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin Chem 2003; 49: 1956-57.
23. Gerlach RF, Uzuelli JA, Souza-Tarla CD, Tanus-Santos JE. Effect of anticoagulants on plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 20O5; 344: 147-49.
24. Souza-Tarla CD, Uzuelli JA, Machado AA, Gerlach RF, Tanus-Santos JE. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin Biochem 2005; 38: 410-14.
25. Gerlach RF, Tanus-Santos JE. Misuse of serum matrix metalloproteinase (MMP)-9 and tissue inhibitor of metalloproteinase (TIMP)-1 as a biomarker in multiple sclerosis. Mult Scler 2006; 12: 120 (Letter).
26. Jung K. Serum or plasma: what kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors? J Neuroimmunol 2005; 162: 1-2 (Letter).
27. Kleiner DE, Stetler-Stevenson WG. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994; 218: 325-29.
28. Mollined F, Schneider DL. Intracellular organelle motility and membrane fusion processes in human neutrophils upon cell activation. FEBS Lett 1987; 217: 158-62.
29. Belaaouaj AA, Li A, Wun TC, Welgus HG, Shapiro SD. Matrix metalloproteinases cleave tissue factor pathway inhibitor. Effects on coagulation. J Biol Chem 2000; 275: 27123-28.
30. Opdenakker G, Van den Steen PE, Dubois B, Nelissen I, Van Coillie E, Masure S et al. Gelatinase B functions as regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851-59.
31. Fontaine V, Jacob MP, Houard X, Rossignol P, Plissonnier D, Angles-Cano E et al. Involvement of the mural thrombus as a site of protease release and activation in human aortic aneurysm. Am J Pathol 2002; 161: 1701-10.
32. Jung K, Nowak L, Lein M, Lein M, Henke W, Schnorr D, Loening SA. Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin Chem 1996; 42: 2043-45.
33. Lein M, Novak L, Jung K, Koenig F, Lichtinghagen R, Schnorr D et al. Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. Clin Biochem 1997; 30: 491-96.
34. Kazes I, Elalamy I, Sraer JD, Hatmi M, Nguyen G. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood 2000; 96: 3064-69.
35. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, Sawicki G, Wozniak M, Radomski MW et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost 1999; 82: 1730-35.
36. Shen JR, Fong TH, Liu CM, Shen MY, Chen TL, Chang Y et al. Expression of matrix metalloproteinase-9 in human platelets: regulation of platelet activation in in vitro and in vivo studies. Br J Pharmacol 2004; 143: 193-201.
37. Troiano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M et al. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 1999; 53: 1402-408.
38. Meisser A, Cohen M, Bischof P. Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin Chem 2005; 51: 274-76.
39. Kivisakk P, Liu Z, Trebst C, Tucky B, Wu L, Stine J et al. Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes. Methods 2003; 29: 319-25.
40. Nelissen I, Gveric D, van Noort JM, Cuzner ML, Opdenakker G. PECAM-1 and gelatinase B coexist in vascular cuffs of multiple sclerosis lesions. Neuropathol Appl Neurobiol 2006; 32: 15-22.
41. Hartel C, Bein G, Muller-Steinhardt M, Kluter H. Ex vivo induction of cytokine mRNA expression in human blood samples. J Immunol Methods 2001; 249: 63-71.